These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 32072356)

  • 1. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
    Li T; Jia DD; Teng LS
    Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
    J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Maio M; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan P; Ibrahim N; Marreaud S; van Akkooi ACJ; Suciu S; Robert C
    N Engl J Med; 2018 May; 378(19):1789-1801. PubMed ID: 29658430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
    Eggermont AM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Lorigan P; Grebennik D; Kreplere C; Marreaud S; Suciu S; Robert C
    Eur J Cancer; 2024 Nov; 211():114327. PubMed ID: 39288737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
    Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
    Ren ZG; Xu Y; Hua ZZ; Mo ZY; Wang LW; Shi GB; Liu WL; Sun W; Zheng BQ; Wang CM; Jin YJ; Chen Y
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):973-980. PubMed ID: 37968084
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
    Tarhini AA; Lee SJ; Hodi FS; Rao UNM; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
    J Clin Oncol; 2020 Feb; 38(6):567-575. PubMed ID: 31880964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
    Luke JJ; Ascierto PA; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Long GV
    J Clin Oncol; 2024 May; 42(14):1619-1624. PubMed ID: 38452313
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
    Kennedy OJ; Glassee N; Kicinski M; Blank CU; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Giacomo AMD; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Gandini S; Buhrer E; Suciu S; Robert C; Eggermont AMM; Mandala M; Lorigan P; Valpione S
    Eur J Cancer; 2024 Apr; 201():113585. PubMed ID: 38402687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
    Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
    J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
    Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
    Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
    Najjar YG; McCurry D; Lin H; Lin Y; Zang Y; Davar D; Karunamurthy A; Drabick JJ; Neves RI; Butterfield LH; Ernstoff MS; Puzanov I; Skitzki JJ; Bordeaux J; Summit IB; Bender JO; Kim JY; Chen B; Sarikonda G; Pahuja A; Tsau J; Alfonso Z; Laing C; Pingpank JF; Holtzman MP; Sander C; Rose A; Zarour HM; Kirkwood JM; Tarhini AA
    Clin Cancer Res; 2021 Aug; 27(15):4195-4204. PubMed ID: 33753453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
    Bührer E; Kicinski M; Mandala M; Pe M; Long GV; Atkinson V; Blank CU; Haydon A; Dalle S; Khattak A; Carlino MS; Meshcheryakov A; Sandhu S; Puig S; Schadendorf D; Jamal R; Rutkowski P; van den Eertwegh AJM; Coens C; Grebennik D; Krepler C; Robert C; Eggermont AMM
    Lancet Oncol; 2024 Sep; 25(9):1202-1212. PubMed ID: 39146951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
    Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
    Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
    Grossmann KF; Othus M; Patel SP; Tarhini AA; Sondak VK; Knopp MV; Petrella TM; Truong TG; Khushalani NI; Cohen JV; Buchbinder EI; Kendra K; Funchain P; Lewis KD; Conry RM; Chmielowski B; Kudchadkar RR; Johnson DB; Li H; Moon J; Eroglu Z; Gastman B; Kovacsovics-Bankowski M; Gunturu KS; Ebbinghaus SW; Ahsan S; Ibrahim N; Sharon E; Korde LA; Kirkwood JM; Ribas A
    Cancer Discov; 2022 Mar; 12(3):644-653. PubMed ID: 34764195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
    Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
    Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
    Weber JS; Carlino MS; Khattak A; Meniawy T; Ansstas G; Taylor MH; Kim KB; McKean M; Long GV; Sullivan RJ; Faries M; Tran TT; Cowey CL; Pecora A; Shaheen M; Segar J; Medina T; Atkinson V; Gibney GT; Luke JJ; Thomas S; Buchbinder EI; Healy JA; Huang M; Morrissey M; Feldman I; Sehgal V; Robert-Tissot C; Hou P; Zhu L; Brown M; Aanur P; Meehan RS; Zaks T
    Lancet; 2024 Feb; 403(10427):632-644. PubMed ID: 38246194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
    Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
    J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.